光啟技術(002625.SZ):警用智能頭盔大規模交付 並投入進博會實戰應用
格隆匯11月4日丨光啟技術(002625.SZ)公佈,2019年11月3日,公司在上海召開“面向5G的AI警務移動終端”發佈會,對外發布單兵AI裝備——警用智能頭盔,宣佈警用智能頭盔大規模交付,並投入第二屆中國國際進口博覽會實戰應用。
光啟單兵AI裝備——警用智能頭盔,作為首款AI單兵裝備,截止目前,已交付上海、重慶等地公安部門。光啟警用智能頭盔在實戰應用中大大提升城市安防效率和能力,進一步彰顯公司在相關領域的戰略實力,為公司可持續發展提供原動力,其相關收入預計將在2019年第四季度予以確認。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.